Evidence map›Paper›PMID 36792604›Full record

ArticleCell death & disease2023

Augmenting hematoma-scavenging capacity of innate immune cells by CDNF reduces brain injury and promotes functional recovery after intracerebral hemorrhage.

Kuan-Yin Tseng, Vassilis Stratoulias, Wei-Fen Hu, Jui-Sheng Wu, Vicki Wang, Yuan-Hao Chen, Anna Seelbach, Henri J Huttunen, Natalia Kulesskaya, Cheng-Yoong Pang and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. The protective effect ofFrontiers in microbiology · 2025
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Transcription Factor NRF2 in Shaping Myeloid Cell Differentiation and Function.Advances in experimental medicine and biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Kuan-Yin TsengDepartment of Neurological Surgery, Tri-Service General Hospital and National Defense Medical Center, No.325, 2nd Sec., Cheng-Kung Road, Nei-Hu District, Taipei City, 114, Taiwan, Taiwan, ROC.
Vassilis StratouliasNeuroscience Center, HiLIFE, Haartmaninkatu 8, FI-00014, University of Helsinki, Helsinki, Finland.
Wei-Fen HuPhD Program in Pharmacology and Toxicology, Tzu Chi University, No.701, Sec.3, Zhong-Yang Road, 970 Hualien County, Hualien, Taiwan.
Jui-Sheng WuDepartment of Neurological Surgery, Tri-Service General Hospital and National Defense Medical Center, No.325, 2nd Sec., Cheng-Kung Road, Nei-Hu District, Taipei City, 114, Taiwan, Taiwan, ROC.
Vicki WangDepartment of Neurological Surgery, Tri-Service General Hospital and National Defense Medical Center, No.325, 2nd Sec., Cheng-Kung Road, Nei-Hu District, Taipei City, 114, Taiwan, Taiwan, ROC.
Yuan-Hao ChenDepartment of Neurological Surgery, Tri-Service General Hospital and National Defense Medical Center, No.325, 2nd Sec., Cheng-Kung Road, Nei-Hu District, Taipei City, 114, Taiwan, Taiwan, ROC.
Anna SeelbachNeuroscience Center, HiLIFE, Haartmaninkatu 8, FI-00014, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-7908-7369
Henri J HuttunenHerantis Pharma Ltd, Plc, Bertel Jungin aukio 1, FI-02600, Espoo, Finland.
Natalia KulesskayaHerantis Pharma Ltd, Plc, Bertel Jungin aukio 1, FI-02600, Espoo, Finland.ORCID 0000-0001-5517-8525
Cheng-Yoong PangInstitute of Medical Sciences, Tzu Chi University, No.701, Sec.3, Zhong-Yang Road, 970 Hualien County, Hualien, Taiwan.ORCID 0000-0002-9063-2858
Jian-Liang ChouGraduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan.
Maria LindahlInstitute of Biotechnology, HiLIFE, Viikinkaari 5D, FI-00014, University of Helsinki, Helsinki, Finland.
Mart SaarmaInstitute of Biotechnology, HiLIFE, Viikinkaari 5D, FI-00014, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-5543-7160
Li-Chuan HuangDepartment of Medical Imaging, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No.707, Sec.3, Zhong-Yang Road, 970 Hualien County, Hualien, Taiwan.
Mikko Airavaara *Neuroscience Center, HiLIFE, Haartmaninkatu 8, FI-00014, University of Helsinki, Helsinki, Finland. mikko.airavaara@helsinki.fi.ORCID 0000-0002-2026-1609
Hock-Kean Liew *PhD Program in Pharmacology and Toxicology, Tzu Chi University, No.701, Sec.3, Zhong-Yang Road, 970 Hualien County, Hualien, Taiwan. hockkean@tzuchi.com.tw.ORCID 0000-0002-5981-4100
University of Helsinki · FITri-Service General Hospital · TWTzu Chi University · TWHerantis Pharma (Finland) · FIHualien Tzu Chi Medical Center · TWNational Defense Medical Center · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During intracerebral hemorrhage (ICH), hematoma formation at the site of blood vessel damage results in local mechanical injury. Subsequently, erythrocytes lyse to release hemoglobin and heme, which act as neurotoxins and induce inflammation and secondary brain injury, resulting in severe neurological deficits. Accelerating hematoma resorption and mitigating hematoma-induced brain edema by modulating immune cells has potential as a novel therapeutic strategy for functional recovery after ICH. Here, we show that intracerebroventricular administration of recombinant human cerebral dopamine neurotrophic factor (rhCDNF) accelerates hemorrhagic lesion resolution, reduces peri-focal edema, and improves neurological outcomes in an animal model of collagenase-induced ICH. We demonstrate that CDNF acts on microglia/macrophages in the hemorrhagic striatum by promoting scavenger receptor expression, enhancing erythrophagocytosis and increasing anti-inflammatory mediators while suppressing the production of pro-inflammatory cytokines. Administration of rhCDNF results in upregulation of the Nrf2-HO-1 pathway, but alleviation of oxidative stress and unfolded protein responses in the perihematomal area. Finally, we demonstrate that intravenous delivery of rhCDNF has beneficial effects in an animal model of ICH and that systemic application promotes scavenging by the brain's myeloid cells for the treatment of ICH.

Indexed as

Brain EdemaBrain InjuriesAnimalsCerebral HemorrhageDisease Models, AnimalHematomaHumansImmunity, InnateInflammationNerve Growth FactorsCDNF protein, humanNerve Growth Factors

Identifiers

PMID36792604
PMCPMC9932138
OpenAlexW4320912770

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.